In committee
POPCaP Authorization Act of 2026
Veterans diagnosed with prostate or other urinary-system cancers will gain access to specialized genetic testing, personalized clinical trials, and travel support to participate in medical studies. The Department of Veterans Affairs (VA) will establish at least 21 specialized cancer care centers nationwide, ensuring each has a dedicated team of oncologists, radiologists, and research staff. A central leadership team will also manage a public registry and develop remote trial options for veterans who cannot easily travel to a facility.
People affected—The operative text does not provide a specific count or estimate of the number of veterans currently diagnosed with prostate or non-prostate genitourinary cancers who would be eligible for the program.
Fiscal magnitude$46.5Mprovisional · pending reviewSection 2(a)(7330E)(i) authorizes $15,500,000 for each of fiscal years 2027 through 2029, totaling $46,500,000 over the three-year period. Additional funding floors are established in Section 2(c)(2) based on January 2023 levels, but the specific dollar amounts for those floors are not stated in the text.
Reach55provisional · pending reviewrigor: heuristic llm
What this bill touches.
Spending vs. restraint+25Public R&D+35
Who it helps · who it burdens.
Who it helps
- Veterans with prostate or non-prostate genitourinary cancersVeterans diagnosed with prostate or non-prostate genitourinary cancers gain eligibility to enroll in a new precision oncology program that provides specialized medical services, genetic sequencing, clinical trials, and travel support (Sec. 2(a)(7330E)(b)-(c)).
Who it burdens
- Department of Veterans AffairsThe Department of Veterans Affairs must establish the precision oncology program, staff at least 21 Centers of Excellence with specific medical specialists, conduct regular performance reviews, and submit progress reports to Congress. It is also prohibited from cutting prostate cancer funding or staff below January 2023 levels until 2030 (Sec. 2(a)-(d), Sec. 3).
Who backs it
- Federal taxpayersFederal taxpayers fund the precision oncology program through authorized appropriations of $15.5 million for each of fiscal years 2027 through 2029 (Sec. 2(a)(7330E)(i)).